Grifols
- Country
- 🇪🇸Spain
- Ownership
- Subsidiary, Public
- Established
- 1940-01-01
- Employees
- 23.7K
- Market Cap
- $6.8B
- Website
- http://www.grifols.com
- Introduction
Grifols SA engages in the production of plasma derivatives. It operates through the following segments: Bioscience, Hospital, Diagnostic, Bio Supplies, and Others. The Bioscience Segment includes all activities related with products deriving from human plasma for therapeutic use. The Hospital Segment comprises of all non-biological pharmaceutical products and medical supplies manufactured by group companies earmarked for hospital pharmacy. The Diagnostic Segment deals with the marketing of diagnostic testing equipment, reagents, and other equipment. The Bio Supplies segment consists of all transactions related to biological products for non-therapeutic use. The Others segment focuses on the rendering of manufacturing services to third party companies. The company was founded by José Antonio Grifols Roig on November 18, 1940 and is headquartered in Barcelona, Spain.
Rapid Infusion Of Immune Globulin Intravenous (IGIV) In Patients With ITP
- Conditions
- Purpura, Thrombocytopenic, Idiopathic
- Interventions
- Drug: Immune Globulin IV [Human], 10% Caprylate/Chromatography Purified
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2016-04-27
- Lead Sponsor
- Grifols Therapeutics LLC
- Target Recruit Count
- 8
- Registration Number
- NCT00220727
- Locations
- 🇺🇸
New York Presbyterian Hospital, New York, New York, United States
Immune Globulin Intravenous (IGIV) For Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
- Conditions
- Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
- Interventions
- Drug: Albumin (Human) 25%, United States Pharmacopeia (USP)Drug: Immune Globulin IV (Human), 10% Caprylate/Chromatography Purified
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2016-03-23
- Lead Sponsor
- Grifols Therapeutics LLC
- Target Recruit Count
- 117
- Registration Number
- NCT00220740
- Locations
- 🇺🇸
Saint Louis University Medical Center, St. Louis, Missouri, United States
🇨🇿Fakultní nemocnice Ostrava, Ostrava-Poruba, Czech Republic
🇵🇱Centre of Clinical Neurology, Neurology Department, Cracow, Poland
Use of Immune Globulin Intravenous (Human) To Treat Age-Related Macular Degeneration
- Conditions
- Macular Degeneration
- Interventions
- Drug: Immune Globulin Intravenous [Human], 10% Caprylate/Chromatography PurifiedDrug: Albumin (Human) 25%, United States Pharmacopeia (USP)
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2016-03-21
- Lead Sponsor
- Grifols Therapeutics LLC
- Target Recruit Count
- 96
- Registration Number
- NCT00220805
- Locations
- 🇩🇪
Klininkum der Eberhard-Karls-Universitat Tubingen, Universitats-Augenklinik, Tubingen, Germany
🇩🇪Universitatsklinikum Aachen, Augenklinik, Aachen, Germany
🇩🇪Augenklinik Tausendfensterhaus, Duisburg, Germany
Rapid Infusion of Immune Globulin Intravenous (Human) In Primary Immunodeficiency Patients
- Conditions
- Immunologic Deficiency SyndromeAgammaglobulinemiaSevere Combined ImmunodeficiencyWiskott-Aldrich SyndromeCommon Variable Immunodeficiency
- Interventions
- Drug: Immune Globulin Intravenous [Human], 10% Caprylate/Chromatography PurifiedDrug: Dextrose, 5% in Water
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2009-09-25
- Lead Sponsor
- Grifols Therapeutics LLC
- Target Recruit Count
- 100
- Registration Number
- NCT00220766
- Locations
- 🇺🇸
The Clinical Trials Center, Children's Hospital, New Orleans, Louisiana, United States
🇺🇸National Jewish Medical and Researach Center, Denver, Colorado, United States
🇺🇸International Center for Interdisciplinary Studies of Immunology, Washington, District of Columbia, United States
Immune Globulin Intravenous (IGIV) To Treat Relapsing, Remitting Multiple Sclerosis
- Conditions
- Multiple Sclerosis, Relapsing-Remitting
- Interventions
- Drug: Albumin (Human) 25%, United States Pharmacopeia (USP)Drug: Immune Globulin IV [Human], 10% Caprylate/Chromatography Purified
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2016-04-27
- Lead Sponsor
- Grifols Therapeutics LLC
- Target Recruit Count
- 128
- Registration Number
- NCT00220779
- Locations
- 🇨🇿
Všeobecná fakultní nemocnice, Prague 2, Czech Republic
🇨🇦Foothills Hospital, Calgary, Alberta, Canada
🇺🇸Neurology Health Care Service, Fletcher Allen Health Care, Burlington, Vermont, United States